Study of S-3304 in Patients With Locally Advanced Non-Small Cell Lung Cancer
| Status: | Completed |
|---|---|
| Conditions: | Lung Cancer, Lung Cancer, Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - 85 |
| Updated: | 5/4/2018 |
| Start Date: | February 2003 |
| End Date: | October 26, 2006 |
A Phase I/II Study of the Safety, Pharmacokinetic Interaction and Efficacy of S-3304 in Combination With Standard Therapy in Patients With Locally Advanced Non-small Cell Lung Cancer.
A study to measure the safety and effectiveness of S-3304 when given in combination with
conventional chemo-radiation therapy in patients with locally advanced non-small cell lung
cancer.
conventional chemo-radiation therapy in patients with locally advanced non-small cell lung
cancer.
A two part study to evaluate the safety and efficacy of S-3304 in combination with standard
therapy in patients with locally advanced non-small cell lung cancer. The first part of the
study is a Phase I design to evaluate the maximum tolerated dose of S-3304 when given in
combination with radiation and paclitaxel/carboplatin chemotherapy that is appropriate for
further evaluation. The second part of the study is a randomized Phase II design to evaluate
the efficacy of recommended S-3304 dose in combination with chemo-radiation.
therapy in patients with locally advanced non-small cell lung cancer. The first part of the
study is a Phase I design to evaluate the maximum tolerated dose of S-3304 when given in
combination with radiation and paclitaxel/carboplatin chemotherapy that is appropriate for
further evaluation. The second part of the study is a randomized Phase II design to evaluate
the efficacy of recommended S-3304 dose in combination with chemo-radiation.
INCLUSION CRITERIA
- newly diagnosed non-small cell lung cancer of stage IIIA non-resectable or of stage
IIIB without pleural effusion
- ECOG performance status 0-1
- adequate organ function
- clinically indicated and able to receive conventional chemoradiation therapy
EXCLUSION CRITERIA
- patients with prior history of cancer, other than basal cell carcinoma after
appropriate treatment, or prior systemic chemotherapy treatment
- patients with other serious intercurrent illness including HIV/AIDS, or
contraindicated for paclitaxel/carboplatin or thoracic irradiation treatment
We found this trial at
5
sites
Cleveland Clinic Cleveland Clinic is committed to principles as presented in the United Nations Global...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials